United States FDA approves Merrimack's ONIVYDE in combination with fluorouracil and leucovorin.
M2 EQUITYBITES-October 23, 2015-United States FDA approves Merrimack's ONIVYDE in combination with fluorouracil and leucovorin
(C)2015 M2 COMMUNICATIONS http://www.m2.com
The United States FDA has approved Merrimack's (NASDAQ: MACK) ONIVYDE (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin (LV) on October 22.
The product is intended for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
ONIVYD is a proprietary liposomal encapsulation of irinotecan, a topoisomerase inhibitor. The NDA for ONIVYDE was based on the results of the international Phase three study (NAPOLI-1). ONIVYDE plus 5-FU/LV achieved the study's primary endpoint by indicating a clinically and statistically significant improvement in overall survival, and demonstrating improvement in progression free survival compared to the control group of patients who received 5-FU/LV alone.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Oct 23, 2015|
|Previous Article:||Hartford announces dividend of USD0.21 per share for quarter.|
|Next Article:||Clean Diesel Technologies names Matthew Beale as CEO.|